ILIAS Biologics CEO On Opening Pandora’s Box For Exosome Therapeutics
Executive Summary
Emerging Company Profile: South Korea-based ILIAS Biologics aims to establish an exosome therapeutic development pathway using its platform technology EXPLOR, which is said to enable loading large therapeutic proteins into exosomes and stably deliver encapsulated cargo proteins to target cells.
You may also be interested in...
Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
GC LabCell Taps Alliances In Bid For Lead NK Cell Position
After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.
Korea To Keep Tight Policy Focus On COVID-19 This Year
South Korea is ramping up policy and financial support in its continuing efforts to control COVID-19, with new drugs and vaccines set to benefit amid broader infectious disease control measures.
Need a specific report? 1000+ reports available
Buy Reports